TY - JOUR
T1 - Discordant effects of glucosamine on insulin-stimulated glucose metabolism and phosphatidylinositol 3-kinase activity
AU - Hawkins, Meredith
AU - Hu, Meizhu
AU - Yu, Jinghua
AU - Eder, Howard
AU - Vuguin, Patricia
AU - She, Li
AU - Barzilai, Nir
AU - Leiser, Margarita
AU - Backer, Jonathan M.
AU - Rossetti, Luciano
PY - 1999/10/29
Y1 - 1999/10/29
N2 - The impact of increased Glen availability on insulin-stimulated p85/p110 phosphatidylinositol 3-kinase (PI3K) activity in skeletal muscle was examined in relation to GlcN-induced defects in peripheral insulin action. Primed continuous GlcN infusion (750 μmol/kg bolus; 30 μmol/kg·min) in conscious rats limited both maximal stimulation of muscle PI3K by acute insulin (I) (1 unit/kg) bolus (I + GlcN = 1.9-fold versus saline = 3.3-fold above fasting levels; p < 0.01) and chronic activation of PI3K following 3-h euglycemic, hyperinsulinemic (18 milliunits/kg·min) clamp studies (I + GlcN = 1.2-fold versus saline = 2.6-fold stimulation;p < 0.01). To determine the time course of GlcN-induced defects in insulin-stimulated PI3K activity and peripheral insulin action, GlcN was administered for 30, 60, 90, or 120 min during 2-h euglycemic, hyperinsulinemic clamp studies. Activation of muscle PI3K by insulin was attenuated following only 30 rain of GlcN infusion (GlcN 30 min = 1.5-fold versus saline = 2.5-fold stimulation; p < 0.05). In contrast, the first impairment in insulin-mediated glucose uptake (Rd) developed following 110 min of GlcN infusion (110 min = 39.9 ± 1.8 versus 30 min = 42.8 ± 1.4 mg/kg·min, p < 0.05). However, the ability of insulin to stimulate phosphatidylinositol 3,4,5-trisphosphate production and to activate glycogen synthase in skeletal muscle was preserved following up to 180 min of GlcN infusion. Thus, increased GlcN availability induced (a) profound and early inhibition of proximal insulin signaling at the level of PI3K and (b) delayed effects on insulin-mediated glucose uptake, yet (c) complete sparing of insulin-mediated glycogen synthase activation. The pattern and time sequence of GlcN-induced defects suggest that the etiology of peripheral insulin resistance may be distinct from the rapid and marked impairment in insulin signaling.
AB - The impact of increased Glen availability on insulin-stimulated p85/p110 phosphatidylinositol 3-kinase (PI3K) activity in skeletal muscle was examined in relation to GlcN-induced defects in peripheral insulin action. Primed continuous GlcN infusion (750 μmol/kg bolus; 30 μmol/kg·min) in conscious rats limited both maximal stimulation of muscle PI3K by acute insulin (I) (1 unit/kg) bolus (I + GlcN = 1.9-fold versus saline = 3.3-fold above fasting levels; p < 0.01) and chronic activation of PI3K following 3-h euglycemic, hyperinsulinemic (18 milliunits/kg·min) clamp studies (I + GlcN = 1.2-fold versus saline = 2.6-fold stimulation;p < 0.01). To determine the time course of GlcN-induced defects in insulin-stimulated PI3K activity and peripheral insulin action, GlcN was administered for 30, 60, 90, or 120 min during 2-h euglycemic, hyperinsulinemic clamp studies. Activation of muscle PI3K by insulin was attenuated following only 30 rain of GlcN infusion (GlcN 30 min = 1.5-fold versus saline = 2.5-fold stimulation; p < 0.05). In contrast, the first impairment in insulin-mediated glucose uptake (Rd) developed following 110 min of GlcN infusion (110 min = 39.9 ± 1.8 versus 30 min = 42.8 ± 1.4 mg/kg·min, p < 0.05). However, the ability of insulin to stimulate phosphatidylinositol 3,4,5-trisphosphate production and to activate glycogen synthase in skeletal muscle was preserved following up to 180 min of GlcN infusion. Thus, increased GlcN availability induced (a) profound and early inhibition of proximal insulin signaling at the level of PI3K and (b) delayed effects on insulin-mediated glucose uptake, yet (c) complete sparing of insulin-mediated glycogen synthase activation. The pattern and time sequence of GlcN-induced defects suggest that the etiology of peripheral insulin resistance may be distinct from the rapid and marked impairment in insulin signaling.
UR - http://www.scopus.com/inward/record.url?scp=0033615599&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033615599&partnerID=8YFLogxK
U2 - 10.1074/jbc.274.44.31312
DO - 10.1074/jbc.274.44.31312
M3 - Article
C2 - 10531330
AN - SCOPUS:0033615599
SN - 0021-9258
VL - 274
SP - 31312
EP - 31319
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 44
ER -